Servicio de Urología, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Servicio de Urología, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.
Actas Urol Esp (Engl Ed). 2022 Jun;46(5):310-316. doi: 10.1016/j.acuroe.2021.11.003. Epub 2022 May 12.
Rezūm® system is a minimally invasive transurethral therapy that uses convective water vapor energy to ablate prostatic tissue. The objective is to report 1-year functional and security outcomes obtained by using this technique in real clinical practice.
Prospective study conducted in 5 Spanish hospitals for the treatment of LUTS secondary to BPH using the Rezūm® system. Patients with prostatic medium lobe (ML) and urethral catheter carriers were also included. Pre- and post-operative data were collected using IPSS, IIEF-5 and QoL questionnaires, flowmetry and post-void residual volume. Complications and retreatment rate at one-year follow-up were also reported.
137 patients, including 64 with ML and 10 patients with urinary retention were treated. Median prostate volume was 50 cm (15-131). At 3 months follow-up, significant improvement was observed in IPSS (-6.37 points), Qmax (+4.95 mL/s) and QoL (-1.29); and was maintained until 12 months: -10.78 points, +4.62 mL/s and -2.73 respectively (p < 0.001). No significant changes were observed in the sexual sphere. All complications were mild (≤ Clavien II). Retreatment rate at one year was 4%.
Short-term results of this technique are promising, showing improvement in terms of functional outcomes, with no impact on the sexual sphere or complications. Longer term follow-up should include treatment durability and comparison to standard BPH treatments.
Rezūm®系统是一种微创经尿道治疗方法，利用对流水蒸气能量来消融前列腺组织。本研究旨在报告在真实临床实践中使用该技术获得的 1 年功能和安全性结果。
对 5 家西班牙医院使用 Rezūm®系统治疗 BPH 引起的下尿路症状（LUTS）的患者进行前瞻性研究。还纳入了前列腺中叶（ML）和导尿管携带者的患者。使用 IPSS、IIEF-5 和 QoL 问卷、尿流率和残余尿量收集术前和术后数据。还报告了 1 年随访时的并发症和再治疗率。
共治疗了 137 例患者，包括 64 例 ML 患者和 10 例尿潴留患者。前列腺体积中位数为 50cm³（15-131）。在 3 个月随访时，IPSS（-6.37 分）、Qmax（+4.95mL/s）和 QoL（-1.29）显著改善，并且持续到 12 个月：-10.78 分、+4.62mL/s 和-2.73（p<0.001）。性领域没有观察到显著变化。所有并发症均为轻度（≤Clavien II）。1 年再治疗率为 4%。
该技术的短期结果很有前景，在功能结果方面显示出改善，对性领域或并发症没有影响。长期随访应包括治疗持久性，并与标准 BPH 治疗进行比较。
